{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:10Z","timestamp":1791920890395,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI068633"],"award-info":[{"award-number":["UM1AI068633"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Microbicide Trials Network 042 study (MTN-042\/DELIVER) is a two-arm, randomized, open-label Phase 3b trial that is evaluating the safety, adherence, and acceptability of the monthly ring and daily oral PrEP among HIV-uninfected pregnant people in four African countries. This analysis focuses on acceptability data captured qualitatively from a subset (n\u2009=\u200948) of the 150 people in the first cohort of the trial who were enrolled in late-stage pregnancy at 36 to 38\u00a0weeks gestational age and followed until after delivery. Single IDIs were conducted by trained interviewers at each clinic site using a semi-structured guide. Data excerpts of key codes pertaining to acceptability, pregnancy, and maternal health were summarized, reviewed and interpreted by multinational analyst teams. Although the product use period was relatively short, the data suggested several acceptability findings that may directly translate to longer durations of product use in pregnancy. The first was the overarching maternal sentiment that being able to protect both oneself and their baby was highly valued. The second was the importance of counseling support from providers not only because participants used methods that might generate side effects, but because pregnancy itself is a period with its own set of side effects. The third was that, similar to non-pregnant participants in other trials, here study products were generally liked and described as easy to use. Concerns about ring and oral PrEP use could be addressed with provider counseling and support and should form an essential component rollout among pregnant people. <\/jats:p>","DOI":"10.1007\/s10461-023-04203-z","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T04:28:12Z","timestamp":1699331292000},"page":"963-973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5477-4445","authenticated-orcid":false,"given":"Elizabeth T.","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogen","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Fairlie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bunge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Mathebula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Etima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca","family":"Mutero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linly","family":"Senyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C. D.","family":"Stoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Piper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"van der Straten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"issue":"9492","key":"4203_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(05)67481-8","volume":"366","author":"RH Gray","year":"2005","unstructured":"Gray RH, Li X, Kigozi G, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (Lond, Engl). 2005;366(9492):1182\u20138.","journal-title":"Lancet (Lond, Engl)"},{"issue":"6","key":"4203_CR2","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/AOG.0b013e3181e00955","volume":"115","author":"GS Birkhead","year":"2010","unstructured":"Birkhead GS, Pulver WP, Warren BL, Hackel S, Rodr\u00edguez D, Smith L. Acquiring human immunodeficiency virus during pregnancy and mother-to-child transmission in New York: 2002\u20132006. Obstet Gynecol. 2010;115(6):1247\u201355.","journal-title":"Obstet Gynecol"},{"key":"4203_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001868","author":"ET Montgomery","year":"2018","unstructured":"Montgomery ET, Stadler J, Naidoo S, et al. Reasons for non-adherence to the dapivirine vaginal ring: results of the MTN-032\/AHA study. AIDS. 2018. https:\/\/doi.org\/10.1097\/QAD.0000000000001868.","journal-title":"AIDS"},{"issue":"8","key":"4203_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31(8):1159\u201367.","journal-title":"AIDS"},{"issue":"4","key":"4203_CR5","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1097\/QAI.0000000000002590","volume":"86","author":"K Naidoo","year":"2021","unstructured":"Naidoo K, Mansoor LE, Katz AWK, et al. Qualitative perceptions of dapivirine VR adherence and drug level feedback following an open-label extension trial. J Acquir Immune Defic Syndr. 2021;86(4):e90\u20136.","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"9","key":"4203_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","volume":"14","author":"RM Grant","year":"2014","unstructured":"Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4203_CR7","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s10461-012-0317-8","volume":"17","author":"EM Van der Elst","year":"2012","unstructured":"Van der Elst EM, Mbogua J, Operario D, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2012;17(6):2162\u201372.","journal-title":"AIDS Behav."},{"issue":"16","key":"4203_CR8","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1097\/QAD.0000000000000801","volume":"29","author":"A van der Straten","year":"2015","unstructured":"van der Straten A, Montgomery ET, Musara P, et al. Disclosure of pharmacokinetic drug results to understand nonadherence. AIDS. 2015;29(16):2161\u201371.","journal-title":"AIDS"},{"issue":"4","key":"4203_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125458","volume":"10","author":"A Corneli","year":"2015","unstructured":"Corneli A, Perry B, Agot K, Ahmed K, Malamatsho F, Van Damme L. Facilitators of adherence to the study pill in the FEM-PrEP clinical trial. PLoS ONE. 2015;10(4): e0125458.","journal-title":"PLoS ONE"},{"issue":"11","key":"4203_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25634","volume":"23","author":"ER Brown","year":"2020","unstructured":"Brown ER, Hendrix CW, van der Straten A, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23(11): e25634.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"4203_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25536","volume":"23","author":"A van der Straten","year":"2020","unstructured":"van der Straten A, Ryan JH, Reddy K, et al. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J Int AIDS Soc. 2020;23(6): e25536.","journal-title":"J Int AIDS Soc"},{"key":"4203_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"4203_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121\u201332.","journal-title":"N Engl J Med"},{"key":"4203_CR14","unstructured":"MT Network. Dapivirine Vaginal Ring-004 overview and regulatory pathway. Paper presented at MTN-042 Stakeholder\u2019s Meeting 2018, Johannesburg, South Africa."},{"key":"4203_CR15","unstructured":"Makanani B BJ, Palanee-Philips T, et al. Pregnancy incidence and outcomes among women using the dapivirine vaginal ring. Paper presented at Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, USA, 2017."},{"issue":"9","key":"4203_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25378","volume":"22","author":"JC Dettinger","year":"2019","unstructured":"Dettinger JC, Kinuthia J, Pintye J, et al. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya. J Int AIDS Soc. 2019;22(9): e25378.","journal-title":"J Int AIDS Soc"},{"key":"4203_CR17","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, et al. Female HIV acquisition per sex act is elevated in late pregnancy and postpartum. Paper presented at 25th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 2018."},{"key":"4203_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002132","volume":"13","author":"KKHC Mugwanya","year":"2016","unstructured":"Mugwanya KKHC, Mugo NR, et al. Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med. 2016;13: e1002132.","journal-title":"PLoS Med"},{"key":"4203_CR19","unstructured":"Antiretroviral Pregnancy Registry. Antiretroviral Pregnancy Registry (APR) international interim report. 1 January 1989 to 31 January 2017. Wilmington, NC: Registry Coordinating Center; 2017."},{"key":"4203_CR20","unstructured":"Siberry GK TC, Stranix-Chibanda L, et al. Impact of Maternal Tenofovir Use on HIV-Exposed Newborn Bone Mineral. Paper presented at Conference on Retroviruses and Opportunistic Infections (CROI). Boston: CROI; 2016."},{"issue":"1","key":"4203_CR21","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/S2352-3018(19)30335-2","volume":"7","author":"J Kinuthia","year":"2020","unstructured":"Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38\u201348.","journal-title":"Lancet HIV"},{"issue":"9","key":"4203_CR22","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1093\/cid\/ciaa181","volume":"71","author":"J Pintye","year":"2020","unstructured":"Pintye J, Kinuthia J, Abuna F, et al. Frequency and predictors of tenofovir-diphosphate detection among young Kenyan women in a real-world pre-exposure prophylaxis implementation program. Clin Infect Dis. 2020;71(9):e509\u201312.","journal-title":"Clin Infect Dis"},{"key":"4203_CR23","unstructured":"World Health Organization. WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection; 2021. https:\/\/www.who.int\/news\/item\/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection. Accessed 08 Nov 2021."},{"key":"4203_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003312","author":"KE Bunge","year":"2023","unstructured":"Bunge KE, Balkus J, Mhlanga F, et al. Deliver: a safety study of a dapivirine vaginal ring and oral PrEP during pregnancy. J Acquir Immune Defic Syndr. 2023. https:\/\/doi.org\/10.1097\/QAI.0000000000003312.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"4203_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12913-017-2031-8","volume":"17","author":"M Sekhon","year":"2017","unstructured":"Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17(1):88.","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"4203_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259779","volume":"16","author":"M Sekhon","year":"2021","unstructured":"Sekhon M, van der Straten A. Pregnant and breastfeeding women\u2019s prospective acceptability of two biomedical HIV prevention approaches in Sub Saharan Africa: a multisite qualitative analysis using the theoretical framework of acceptability. PLoS ONE. 2021;16(11): e0259779.","journal-title":"PLoS ONE"},{"key":"4203_CR27","unstructured":"Owor M, Noguchi L, Horne E, Matimbira M, Ssemambo PK, Madhlopa-Mandiwa V, Scheckter R, Gundacker HM, Richardson B, Marzinke MA, Anderson PL, Bunge KE, Chakhtoura N, Piper J, Balkus J. Dapivirine ring safety and drug detection in breastfeeding mother\u2013infant pairs. Seattle: CROI; 2023."},{"issue":"5","key":"4203_CR28","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10461-014-0950-5","volume":"19","author":"ET Montgomery","year":"2014","unstructured":"Montgomery ET, van der Straten A, Stadler J, et al. Male partner influence on women\u2019s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of \u201cunderstanding.\u201d AIDS Behav. 2014;19(5):784\u201393.","journal-title":"AIDS Behav"},{"issue":"1","key":"4203_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12913-022-07577-3","volume":"22","author":"M Sekhon","year":"2022","unstructured":"Sekhon M, Cartwright M, Francis JJ. Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions. BMC Health Serv Res. 2022;22(1):279.","journal-title":"BMC Health Serv Res"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-023-04203-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-023-04203-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T08:24:48Z","timestamp":1708935888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-023-04203-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["4203"],"URL":"https:\/\/doi.org\/10.1007\/s10461-023-04203-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"28 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"<b>MTN-042\/DELIVER:<\/b> All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the following Institutional Review Boards\/Ethics Committees and Drug Regulatory Authorities: Prevention Sciences Research Committee of the US National Institute of Allergy and Infectious Diseases; US Food and Drug Administration; College of Medicine Research and Ethics Committee; Johns Hopkins School of Public Health Institutional Review Board; Pharmacy, Medicines and Poisons Board of Malawi; Human Research Ethics Committee: (Medical), University of Witwatersrand, Johannesburg; South African Health Products Regulatory Authority; Joint Clinical Research Centre Institutional Review Board; Uganda National Council for Science and Technology; Johns Hopkins Medicine Office of Human Subjects Research Institutional Review Board; National Drug Authority of Uganda; Medical Research Council of Zimbabwe; Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals; Research Council of Zimbabwe; Medicines Control Authority of Zimbabwe.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}